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OBJECTIVE—SIRT1, a class III histone/protein deacetylase, is
known to interfere with the nuclear factor-B (NF-B) signaling
pathway and thereby has an anti-inﬂammatory function. Because
of the central role of NF-B in cytokine-mediated pancreatic
-cell damage, we postulated that SIRT1 might work in pancre-
atic -cell damage models.
RESEARCH DESIGN AND METHODS—RINm5F (RIN) cells
or isolated rat islets were treated with interleukin-1 and inter-
feron-. SIRT1 was activated by resveratrol, a pharmacological
activator, or ectopic overexpression. The underlying mecha-
nisms of SIRT1 against cytokine toxicity were further explored.
RESULTS—Treatment of RIN cells with cytokines induced cell
damage, and this damage was well correlated with the expres-
sion of the inducible form of nitric oxide (NO) synthase (iNOS)
and NO production. However, SIRT1 overexpression completely
prevented cytokine-mediated cytotoxicity, NO production, and
iNOS expression. The molecular mechanism by which SIRT1
inhibits iNOS expression appeared to involve the inhibition of the
NF-B signaling pathway through deacetylation of p65. In addi-
tion, SIRT1 activation by either resveratrol or adenoviral-
directed overexpression of SIRT1 could prevent cytokine toxicity
and maintain normal insulin-secreting responses to glucose in
isolated rat islets.
CONCLUSIONS—This study will provide valuable information
not only into the mechanisms underlying -cell destruction but
also into the regulation of SIRT1 as a possible target to attenuate
cytokine-induced -cell damage. Diabetes 58:344–351, 2009
D
iabetes, which is characterized at the cellular
level by a deﬁcit in -cell mass, is increasing to
epidemic proportions. However, the mecha-
nisms underlying -cell destruction are not
clear, although it has been suggested that cytokines may
be involved. For example, in type 1 diabetes, cytokines are
important mediators in the impaired function and destruc-
tion of pancreatic -cells. In pancreatic islets, interleukin
(IL)-1, either alone or in combination with interferon
(IFN)-, causes the production of nitric oxide (NO)
through the inducible form of NO synthase (iNOS) (1–4).
IL-1 exerts its primary effects through the transcrip-
tional nuclear factor-B (NF-B) pathway. NF-B is ini-
tially located in the cytoplasm in an inactive form
complexed with inhibitor of B( I B), an inhibitory factor
of NF-B. Various inducers can cause dissociation of this
complex, presumably by phosphorylation of IB, resulting
in NF-B being released from the complex. NF-B then
translocates to the nucleus, where it interacts with speciﬁc
DNA recognition sites to mediate gene transcription such
as iNOS and cyclooxygenase-2 (5–7). NF-B signaling is
modulated by posttranslational modiﬁcations, including
reversible acetylation of the p65 subunit (8). Five main
acetylation sites have been identiﬁed within p65, and the
modiﬁcation of these sites modulates both the DNA-
binding and transcriptional activities. Acetylation at Lys
221
enhances DNA binding by p65 and impairs its assembly
with IB, whereas acetylation of Lys
310 is required for full
transcriptional activity of p65 (9). Therefore, NF-B–
dependent transactivation depends on the balance be-
tween acetylation and deacetylation status of NF-B.
SIRT1 belongs to class III histone/protein deacetylases
(HDACs) and is a member of the silent information
regulator (Sir2) family. Unlike class I and II HDACs, which
use zinc as a cofactor (10), SIRT1 consumes one NAD
 for
every acetyl group removed from a protein substrate (11).
SIRT1, through its deacetylase activity, plays pivotal roles
in various cellular processes, including gene silencing,
metabolism, stress resistance, and life span extension in
response to caloric restriction (11,12). SIRT1 also pro-
motes cell survival or inhibits apoptotic cell death by
deacetylating the p53 (13), Ku70 (14), and forkhead tran-
scription factor (15,16). Thus, SIRT1 is regarded as a key
regulator of cell defense and survival under various stress
conditions.
One of the hallmarks of calorie restriction is reduced
inﬂammation, and a key regulator of inﬂammation is
NF-B (17–19). Recently, Yang et al. (20) reported that
cigarette smoke decreased the SIRT1 level and increased
acetylation of p65, which was concomitant to increased
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Considering NF-B as a direct target of SIRT1, their results
imply that SIRT-1 may play an important role in the
inﬂammatory process. SIRT1 is constitutively expressed in
the endocrine cells of the islets of Langerhans. To our
knowledge, the only known function of SIRT1 in the islets
is improving insulin secretion by repressing uncoupling
protein 2 (21,22). In this study, we have uncovered a new
role of SIRT1 in the protection of pancreatic -cells from
cytokine toxicity.
RESEARCH DESIGN AND METHODS
Cell culture and reagents. RINm5F (RIN) cells were purchased from the
American Type Culture Collection. IL-1 and IFN- were obtained from R&D
Systems (Minneapolis, MN). The retroviral vector expressing human SIRT1
(wild-type [WT]-SIRT1 and pYESir2), the retroviral vector expressing a
dominant-negative form of human SIRT1 (dominant-negative [DN]-SIRT1 and
pYESir2HY), and the backbone vector for pYESir2 and pYESir2HY, pBABE,
were purchased from Addgene (Cambridge, MA). Amphophenix cells for
packaging retrovirus were provided by G. Nolan (Stanford University, Stan-
ford, CA). All reagents were purchased from Sigma (St. Louis, MO) unless
otherwise noted.
Animals. Five-week-old male ICR mice were purchased from the Orientbio
(Seoungnam, Korea). To induce multiple low-dose streptozotocin (MLDS)-
induced diabetes, once a day for 5 consecutive days, the mice received an
injection of freshly prepared streptozotocin (50 mg/kg body wt i.p.; 0.2 ml)
dissolved in sodium citrate buffer (pH 4.0). Eight-week-old female NOD mice
were purchased from The Jackson Laboratory (Bar Harbor, ME) and housed
at our animal facility for 8 weeks. All experimental procedures were approved
by the Institutional Animal Care and Use Committee at Chonbuk National
University.
Isolation of islets and glucose-stimulated insulin secretion assay.
Pancreatic islets were isolated from male Sprague-Dawley rats using the
collagenase digestion method, as described previously (23). Islets were
pretreated with resveratrol or infected with Ad-SIRT1 and then cultured for
24 h with 2 ng/ml IL-1 and 100 units/ml IFN-. The islets were then washed
three times in Krebs-Ringer bicarbonate buffer (25 mmol/l HEPES, 115 mmol/l
NaCl, 24 mmol/l NaHCO3, 5 mmol/l KCl, 1 mmol/l MgCl2, 2.5 mmol/l CaCl2, and
0.1% BSA, pH 7.4) containing 3 mmol/l D-glucose, and insulin secretion assays
were then performed in the presence of either 5.5 or 20 mmol/l D-glucose. The
insulin content of the medium was then determined by ELISA kit (Linco
Research, St. Charles, MO).
Retroviral infection of WT-SIRT1 and DN-SIRT1. Amphophenix cells
were transfected with retroviral vectors using Lipofectamine 2000 (Invitrogen,
Carlsbad, CA), and on the following day, the media were changed. Thirty
hours after media change, retroviral particle-containing supernatants were
harvested and ﬁltered through a 0.45-m low-protein binding ﬁlter (Millipore,
Bedford, MA). RIN cells were transduced with virus supernatants on a
nontissue culture plate coated with recombinant human ﬁbronectin fragment
CH296 (Retronectin, Takara Shuzo, Japan). Two days later, the transduced
cells were selected with 5 g/ml puromycin (Sigma) for 7 days.
Preparation of the recombinant adenovirus. To prepare SIRT1-expressing
adenovirus, the mouse SIRT1 cDNA was cloned into the KpnI and XhoI sites
of pENTR 2B (Invitrogen), and the SIRT1 cDNA insert was transferred to the
pAd/CMV/V5-DEST vector (Invitrogen) by the Gateway system using LR
Clonase (Invitrogen). The plasmids linearized with PacI (Promega, Madison,
WI) were transfected into 293A cells using Lipofectamine 2000. Then 293A
cells were cultured for 1–2 weeks in RPMI 1640 containing 10% fetal bovine
serum (FBS), with replacement of the medium every 2 days. As a control, the
pAd/CMV/V5-GW/lacZ vector (Invitrogen) was used to produce lacZ-bearing
adenovirus.
SIRT1 HDAC assay. Cells (5  10
6) were homogenized in 100 l CytoBuster
Protein Extraction Buffer (Novagen, Madison, WI). For immunoprecipitation
of SIRT1, primary antibody for SIRT1 (1 g) was mixed with precleared
lysates for1ha t4 ° Cbefore the addition of 20 l protein agarose A/G, and
reactions were tumbled overnight at 4°C. The agarose beads were extensively
washed until the next day and followed by HDAC assay. Equal amounts of
lysates were analyzed for enzyme activity using the HDAC ﬂuorescence
activity assay kit from Millipore.
Cell viability of RIN cells and islets. The viability of RIN cells was
determined by assaying the reduction of 3-(4, 5-dimethylthiazol-2-yl)-2, 5-di-
phenyltetrazolium bromide (MTT) to formazan. A cell proliferation enzyme-
linked immunosorbent assay (5-bromo-2-deoxyuridine [BrdU] kit; Amersham
Biosciences, Piscataway, NJ) was used to measure the incorporation of BrdU
during DNA synthesis following the manufacturer’s protocols. Islet viability
was evaluated by acridine orange and propidium iodide staining under
ﬂuorescence microscopy. Brieﬂy, islets that had been treated with cytokines
were stained with 10 g/ml acridine orange and 1 g/ml propidium iodide for
10 min at 37°C. After careful washing, islets were placed on coverslips and
examined by ﬂuorescence microscopy. Live cells were identiﬁed by a green
staining (acridine orange staining), whereas dead cells were brown-red
(propidium iodide staining). For histological analysis, islets were ﬁxed over-
night in a solution of 6.5% glutaraldehyde. The islets were then centrifuged in
1% agarose solution and embedded in parafﬁn. Four-micrometer sections were
prepared, and cell viability was determined by hematoxylin-eosin staining.
The sections were labeled for anti-insulin antibody (Santa Cruz Biochemicals,
Santa Cruz, CA) or anti-glucagon antibody (Dako, Carpinteria, CA) and then
examined by microscopy.
Nitrite measurement. After treatment with cytokine for 24 h, 100-l aliquots
of the culture supernatants were incubated with 100 l modiﬁed Griess
reagent (1:1 mixture of 1% sulfanilamide in 30% acetic acid and 0.1%
N-(1-naphthyl) ethylenediamine dihydrochloride in 60% acetic acid) at room
temperature for 5 min, at which time the absorbance at 540 nm was measured
using a spectrophotometer.
Whole-cell and nuclear protein extracts. Cells were washed with PBS and
lysed in CytoBuster Protein Extraction Buffer (Novagen). The lysate was
centrifuged at 10,000g for 5 min at 4°C, and the supernatant was used as the
whole-cell protein extract. Cytoplasmic and nuclear extracts were prepared
from cells using the NE-PER Nuclear and Cytoplasmic Extraction Reagents
(Pierce Biotechnology, Rockford, IL).
Western blot analysis. RIN cells or islets were homogenized in 100 l
ice-cold lysis buffer (20 mmol/l HEPES, pH 7.2, 1% Triton X-100, 10% glycerol,
1 mmol/l phenylmethylsulfonyl ﬂuoride, 10 g/ml leupeptin, and 10 g/ml
aprotinin). The homogenates, which contained 20 g protein, were then
separated by SDS-PAGE and transferred to nitrocellulose membranes. The
blot was probed with a 1 g/ml primary antibodies for SIRT2,3,4, p65, -actin,
proliferating cell nuclear antigen (PCNA; Santa Cruz Biochemicals), SIRT1,5,7
(Lifespan Biosciences, Seattle, WA), or acetyl-lysine p65 (Abcam, Cambridge,
MA) and then detected with horseradish peroxidase–conjugated IgG (Zymed,
South San Francisco, CA).
RNA isolation and real-time PCR. RNA was isolated using Trizol reagent
(Invitrogen). RNA was precipitated with isopropanol and dissolved in diethyl
pyrocarbonate–treated distilled water. Total RNA (2 g) was then treated with
RNase-free DNase, and ﬁrst-strand cDNA was generated using the random
hexamer primer provided in the ﬁrst-strand cDNA synthesis kit (Applied
Biosystems, Foster City, CA). Speciﬁc primers for each gene (Table 1) were
designed using primer express software (Applied Biosynthesis). The control
18S ribosomal RNA was purchased from Applied Biosystems and used as the
invariant control. The real-time PCR, which was contained in a ﬁnal volume of
10 l, consisted of 10 ng reverse-transcribed total RNA, 167 nmol/l forward
and reverse primers, and 2 PCR master mix. The PCR was carried out in
384-well plates using the ABI Prism 7900HT Sequence Detection System
(Applied Biosystems). All reactions were conducted in triplicate.
Electrophoretic mobility shift assay. The activation of NF-B was assayed
by a gel mobility shift assay using nuclear extracts from control and treated
cells. An oligonucleotide containing the -chain binding site (B, 5-CCGGT
TAACAGAGGGGGCTTTCCGAG-3) was synthesized and used as a probe for
the gel retardation assay. The two complementary strands were then annealed
and labeled with [-
32P]dCTP. Labeled oligonucleotides (10,000 cpm), 10 g
TABLE 1
Sequences and accession numbers for primers used in real-time
RT-PCR
Gene Sequences for primers
Accession
no.
iNOS FOR: TGGTGAAAGCGGTGTTCTTTG
NM_012611 REV: ACGCGGGAAGCCATGA
COX-2 FOR: TGCTCACTTTGTTGAGTCATTCAC
NM_017232 REV: CATTCCTTCCCCCAGCAA
HO-1 FOR: CAGCCCCACCAAGTTCAAA
BC010757 REV: CAGCCCCACCAAGTTCAAA
MnSOD FOR: GGGCTGGCTTGGCTTCA
NM_017051 REV: AGCAGGCGGCAATCTGTAA
HSP70 FOR: GGCTGATCGGACGGAAGTT
NM_021863 REV: ACGGCCAGTGCTTCATATCC
COX-2, cyclooxygenase-2; FOR, forward; HO-1, heme oxygenase-1;
HSP70, heat shock protein 70; MnSOD, mitochondrial superoxide
dismutase; REV, reverse.
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KCl, 10 mmol/l EDTA, 50% glycerol, 100 ng poly(dIdC), and 1 mmol/l
dithiothreitol] were then incubated for 30 min at room temperature in a ﬁnal
volume of 20 l. Next, the reaction mixtures were analyzed by electrophoresis
on 4% polyacrylamide gels in 0.5  Tris-borate buffer, and the gels were then
dried and examined by autoradiography.
NF-B luciferase assay. Cells were seeded on 24-well culture plates at 2 
10
4 cells/well and adapted for 12 h. Cells were incubated for 1 h with a total
of 170 ng plasmids (85 ng NF-B–dependent luciferase reporter and 85 ng
pcDNA3–-gal), 1 l Tfx-50 reagent (Promega), and 200 l serum-free RPMI.
In all, 800 l RPMI containing FBS was then added, and incubation continued.
After 24 h of incubation, cells were treated with cytokine for 1 h. Luciferase
activity was measured using a luciferase assay system and normalized against
-galactosidase activity.
Statistical analysis. Statistical analysis of the data was performed using
ANOVA and Duncan’s test. Differences with a P 	 0.05 were considered
statistically signiﬁcant.
RESULTS
Decrease of SIRT1 protein levels in cytokine-treated
RIN cells and islets. Western blotting data showed that
various isoforms of SIRT proteins were expressed in RIN
cells with varying degrees (supplementary Fig. S1, avail-
able in an online appendix at http://dx.doi.org/10.2337/
db07-1795). To investigate whether SIRT1 is involved in
cytokine toxicity in pancreatic -cells, we compared
SIRT1 protein levels in control and cytokine-treated RIN
cells (Fig. 1A). Moderate levels of SIRT1 were detected in
RIN cells, and SIRT1 protein level was decreased by
2-ng/ml IL-1 treatment. When RIN cells were treated with
2 ng/ml IL-1 plus 100 units/ml IFN-, SIRT1 protein level
was almost completely lost. We further investigated this
decline in isolated rat islets. Similar level of SIRT1 was
expressed in isolated rat islets, and its expression was also
decreased by cytokine treatment (Fig. 1B). To examine
whether SIRT1 protein level was also decreased in dia-
betic animal models, we immunostained SIRT1 on pancre-
atic sections of MLDS-treated (supplementary Fig. S2A,
available in the online appendix) or NOD mice (supple-
mentary Fig. S2B). As Moynihan et al. (22) reported, SIRT1
was expressed in pancreatic islets of control mice; how-
ever, a relatively lower level of SIRT1 was detected in our
diabetic animal models. These results suggest that the
decrease of SIRT1 in pancreatic -cells is related to the
type 1 diabetes development.
Prevention of IL-1– and IFN-–induced cell death by
SIRT1 overexpression. A reduction in SIRT1 protein
levels in cytokine-induced pancreatic -cell toxicity model
raises the possibility that overexpression of WT- or DN-
SIRT1 might modulate the cytokine toxicity. To address
this question, RIN cells were infected with retroviruses
expressing WT-SIRT1 or DN-SIRT1. Overexpression of
SIRT1 was demonstrated by Western blotting and HDAC
activity assay (Fig. 2A and B). Next, we compared control
and SIRT1-overexpressing RIN cells on cytokine toxicity.
RIN cells were exposed to cytokine for 48 h, and their
viabilities were assessed using an MTT assay (Fig. 3A).
Treatment with IL-1 alone or IL-1 and IFN- signiﬁ-
cantly reduced the cell viability to 80.6 
 10.6 and 48.4 

1.7% of that of the control, respectively. Conversely,
SIRT1-overexpressing RIN cells were resistant against
cytokine, whereas DN-SIRT1–overexpressing RIN cells
were more sensitive to cytokine. The protective effect of
SIRT1 overexpression on cytokine-induced cytotoxicity
was further conﬁrmed by measuring the BrdU incorpora-
tion in RIN cells (Fig. 3B). Results were similar to those of
MTT assay.
Effect of SIRT1 overexpression on IL-1– and IFN-–
induced iNOS expression and NO production. It has
been reported that IL-1– and IFN-–mediated destruc-
tion of -cells is caused by an increase of NO (24,25).
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FIG. 1. Decreased expression of SIRT1 by cytokine in RIN cells (A) and
isolated rat islets (B). RIN cells (5  10
6) or islets (30) were treated
with IL-1 (2 ng/ml) alone or IL-1 and IFN- (100 units/ml). After 48 h
of incubation, Western blotting for SIRT1 was conducted. C: Protein
bands were detected using the enhanced chemiluminescence detection
system and analyzed by imaging densitometry. Each value represents
the mean  SE of six independent experiments. **P < 0.01 vs.
untreated control.
p
B
A
B
E
β-actin
D
N
-
S
I
R
T
1
 
W
T
-
S
I
R
T
1
 
A
B
0
50
100
150
200 **
**
SIRT1(125 kDa)
S
I
R
T
1
 
d
e
a
c
e
t
y
l
a
s
e
 
a
c
t
i
v
i
t
y
(
%
 
o
f
 
c
o
n
t
r
o
l
)
FIG. 2. Ectopic overexpression of SIRT1 regulates HDAC activity in
RIN cells. A: RIN cells (5  10
6) were transduced with retroviruses
expressing WT-SIRT1 or DN-SIRT1, and RIN cell extracts prepared
48 h after viral infection were subjected to Western blot analysis with
anti-SIRT1 antibody. B: Deacetylase activity of overexpressed SIRT1
was measured using ﬂuorogenic substrate as described in RESEARCH
DESIGN AND METHODS. Each value represents the mean  SE of three
independent experiments. **P < 0.01 vs. pBABE.
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in signiﬁcant production of nitrite (a stable oxidized
product of NO) by these cells (Fig. 4A). However, SIRT1
overexpression signiﬁcantly diminished the cytokine-
mediated nitrite production, and this reduction was well
correlated with the lowered cytotoxicity of the cells
(Fig. 3). To examine whether SIRT1 overexpression
inhibited NO production via suppression of iNOS ex-
pression, the changes in iNOS mRNA and proteins were
investigated by real-time PCR and Western blot analysis,
respectively (Fig. 4B and C). iNOS mRNA and protein
expressions were markedly increased in cells treated
with cytokine, whereas SIRT1-overexpressing cells
showed suppressed expression of both the mRNA and
protein levels of iNOS. In contrast, nitrite production
and iNOS expression were signiﬁcantly increased in
DN-SIRT1–overexpressing RIN cells compared with
control cells (P 	 0.01).
Effect of SIRT1 overexpression on IL-1– and IFN-–
induced activation of NF-B pathway. NF-B has been
implicated in the transcriptional regulation of cytokine-
induced iNOS expression. Therefore, we studied the effect
of SIRT1 on the cytokine-stimulated NF-B activation
pathway. Cytokine-treated RIN cells showed increased
DNA binding and transcriptional activities of NF-B, as
demonstrated by electrophoretic mobility shift assay
(EMSA) and luciferase reporter assay, respectively (Fig.
5A and B). Additionally, Western blot analysis conﬁrmed
the increased nuclear translocation of the p65 subunit
(Fig. 5C). However, SIRT1-overexpressing cells showed
signiﬁcant decrease of NF-B activity compared with
control cells. Much evidence has shown that acetylation of
p65 at lysine residues (particularly at 310) is required for
the full transactivation function of p65 (9,26,27). We
therefore determined whether the SIRT1 overexpression
has any role on NF-B acetylation. To address this ques-
tion, cytokine was added for 1 h, and whole-cell lysates
were prepared and analyzed by Western blotting using
anti–acetyl-lysine p65 antibody. The addition of cytokine
effectively acetylated p65 in RIN cells. On overexpression,
SIRT1 suppressed the cytokine-induced acetylation of p65,
whereas DN-SIRT1–overexpressing cells increased the
acetylation of p65 compared with control cells (Fig. 5C).
Because SIRT1 overexpression protected cytokine-
induced -cell death, we tested whether resveratrol, a
SIRT1 activator, modulated the cytokine toxicity. We ﬁrst
conﬁrmed the activation of HDAC activity in RIN cells
after treatment with resveratrol (Fig. 6A). Similar to the
results obtained using the SIRT1-overexpressing RIN cells,
pretreatment with resveratrol abolished the effects of the
cytokines and resulted in levels of NO production and
iNOS expression in terms of both mRNA and protein levels
that were similar to those of the controls (Fig. 6B).
Additionally, NF-B transcriptional activity and acetyla-
tion of p65 induced by cytokine treatment was markedly
suppressed by resveratrol (Fig. 6C and D).
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in islets by resveratrol or Ad-SIRT1. We further assessed
the preventive effects of SIRT1 activation using rat pan-
creatic islets isolated from male Sprague-Dawley rats to
support the physiological importance of the results ob-
tained in the cell line studies. Incubation of rat islets with
cytokines resulted in increases of DNA binding of NF-B,
NO production, and iNOS expression in rat islets, and
pretreatment of the islets with resveratrol abolished all of
the effects of the cytokine (Fig. 7A and B). Next, over-
expression of SIRT1 was achieved by infection of islets
with Ad-SIRT1 (Fig. 7C). Again, SIRT1-overexpressing
islets showed signiﬁcant decrease of nitrite production
and iNOS expression compared with control islets (Fig.
7D). To add functional data, insulin secretion was ob-
served in response to 20 mmol/l glucose. Control islets
secreted insulin at a concentration of 21.3 
 3.1 ng/ml,
whereas insulin secretion from cytokine-treated islets
decreased signiﬁcantly to 9.3 
 1.0 ng/ml (P 	 0.01) (Fig.
7E). As expected, pretreatment with resveratrol or SIRT1
overexpression blocked the effect of the cytokine and
restored islet cell insulin secretion to the control level.
Enhanced SIRT1 function by resveratrol or SIRT1 over-
expression increased the resistance of -cells to cytokine
toxicity, which resulted in the increased viability of islets
(Fig. 7F). Histological analysis stained for insulin or glu-
cagon antibody conﬁrmed that protective effect of SIRT1
was -cell speciﬁc (supplementary Fig. S3, available in the
online appendix).
DISCUSSION
SIRT1, a class III histone/protein deacetylase, interferes
with the NF-B signaling pathway and thereby has an
anti-inﬂammatory function (20). Because of the central
role of NF-B in cytokine-mediated pancreatic -cell dam-
age, we postulated that SIRT1 might work in cytokine-
induced pancreatic -cell damage models. Our results
provide evidence that SIRT1 has a protective effect against
cytokine in RIN cells and islets for the following reasons.
First, addition of cytokine to RIN cells and islets de-
creased SIRT1 protein levels. Second, SIRT1 overexpres-
sion protected RIN cells from cytokine, whereas DN-
SIRT1 overexpression rather aggravated its cytotoxicity.
SIRT1 overexpression suppressed the NF-B transactiva-
tion potential, NF-B–dependent iNOS expression and NO
formation, and cytotoxicity induced by cytokine in RIN
cells. Third, resveratrol and Ad-SIRT1 were also capable of
protecting islets by stimulating SIRT1 and maintaining
normal insulin secretion capacity. These results lead us to
suggest the hypothesis that SIRT1 plays a cytoprotective
role against cytokine in pancreatic -cells.
We ﬁrst showed that SIRT1 protein levels were de-
creased by cytokine both in RIN cells and islets. In this
regard, a recent report by Sun et al. (28) showed the
downregulated SIRT1 protein levels in insulin-resistant
C2C12 myotubes and high-fat diet–fed mice. Using dif-
ferent approaches, other groups also found that stress-
induced cell damage or dysfunction was also associated
with SIRT1 depletion (29,30). Thus, our ﬁndings to-
gether with their results imply that SIRT1 may modulate
the sensitivity of cells against various types of stress
response through regulation of its protein levels or enzyme
activities.
Several cytokines regulate inﬂammatory responses in
pancreatic -cells by modulating the NF-B signaling
pathway. One of these is IL-1, a proinﬂammatory cyto-
kine that has been implicated in early events in -cell
destruction. Suppression of IL-1 production or inhibition
of its interaction with the corresponding cellular receptors
signiﬁcantly inhibits IL-1–mediated deleterious effects on
-cells (31–33). IL-1 activates the extracellular signal-
regulated kinase-1/2, p38 kinase, and c-Jun NH2-terminal
kinase in pancreatic -cells (34,35). However, as we and
others have found, IL-1 exerts its main effects through
the NF-B pathway (1,3,23). Therefore, IL-1–NF-B sig-
naling pathway is considered as the central in cytokine-
induced -cell destruction, and NF-B has been targeted
for studies of the prevention of islet destruction (36–38).
Because NF-B is a molecular target for cytokine toxicity
and deacetylation by SIRT1, we investigated the changes
of NF-B signaling pathways in cytokine-treated SIRT1-
overexpressing RIN cells. SIRT1 overexpression led to
inhibition of NF-B pathway. Compared with control cells,
SIRT1 overexpression decreased DNA binding and tran-
scriptional activities, as demonstrated by Western blot
analysis, and decreased nuclear translocation of p65 pro-
tein, as demonstrated by EMSA and immunoﬂuorescence
staining. Consistent with this, nuclear translocation of p65
and DNA binding were increased in DN-SIRT1–over-
expressing RIN cells than control cells, which is associ-
ated with increased susceptibility to cytokine toxicity. We
found that SIRT1 overexpression could block cytokine-
induced NF-B downstream gene iNOS expression.
Besides iNOS, various other genes, including cyclo-
oxygenase-2, heat shock protein 70, heme oxygenase-1,
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348 DIABETES, VOL. 58, FEBRUARY 2009and mitochondrial superoxide dismutase, are also regu-
lated by NF-B in pancreatic -cells (39,40). As expected,
SIRT1 overexpression moderately decreased cytokine-
induced expression of all of the aforementioned genes
(supplementary Fig. S4, available in the online appendix).
Therefore, we cannot exclude the possibility that SIRT1
induces the beneﬁcial effect by regulating those proteins.
Interestingly, protective effects of SIRT1 in pancreatic
-cells were cytokine speciﬁc. When SIRT1-overexpress-
ing RIN cells were exposed to palmitate (lipotoxicity),
H2O2 (oxidative stress), or thapsigargin (ER stress), pro-
tective effects of SIRT1 were not observed in our experi-
mental conditions (supplementary Fig. S5, available in the
online appendix). This is in contrast with a recent study
obtained from the high-fat diet–fed -cell–speciﬁc SIRT1
(BESTO) mice, where they still maintained enhanced
glucose-stimulated insulin secretion and improved glucose
tolerance (41). These differences might result from the
methodological differences. We used cultured cells and
primary rat islets (type 1 diabetes model), whereas they
obtained in vivo results from a type 2 diabetes model. No
clear insights could be provided at present, and further
studies are required to understand the exact mechanism.
The mechanism of cytoprotection involves a number of
factors, and SIRT1 could participate in this pathway by
affecting target protein levels by transcriptional silencing
through histone modiﬁcation. Alternatively, it might
deacetylate nonhistone proteins such as NF-B in a con-
text-speciﬁc manner. In proving the molecular mecha-
nisms underlying NF-B inactivation by SIRT1, we focused
on the acetylation status of p65. Yeung et al. (9) demon-
strated that p65 could be acetylated at ﬁve lysine residues:
Lys
122, Lys
123, Lys
218, Lys
221, and Lys
310. Among these,
SIRT1 physically interacts and deacetylates Lys
310 of p65
without affecting the other lysine residues. In support of
this, our data also showed that NF-B activation by
cytokine was associated with acetylation of p65 at Lys
310.
In contrast, SIRT1 overexpression induced deacetylation
of p65, which impedes this protein from controlling the
inﬂammatory response. It is not clear whether SIRT1
affects other lysine residues. These results are in accor-
dance with the hypothesis that deacetylation of NF-Bb y
SIRT1 is an important mechanism for cytoprotection. In
addition to SIRT1 overexpression, we further studied
whether the pharmacological activation of SIRT1 by res-
veratrol could protect islets from cytokine toxicity. Res-
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activity was determined 1 h later (A), and nitrite production and iNOS
mRNA and protein expressions were determined 24 h later (C). Tran-
scriptional activity of NF-B( B) and acetylation of p65 (D) were
analyzed by luciferase reporter assay and Western blotting, respectively.
Each value represents the mean  SE of three independent experiments.
**P < 0.01 vs. untreated control; ##P < 0.01 vs. IL-1IFN-.
J.-H. LEE AND ASSOCIATES
DIABETES, VOL. 58, FEBRUARY 2009 349veratrol mimicked the effects of SIRT1 overexpression,
leading to inactivation of NF-B and downregulation of
iNOS expression in response to cytokine treatment. In
addition, resveratrol-treated cells produced a lower
amount of NO than control cells, which leads to resistance
to cytokine toxicity. Considering the similarities between
resveratrol and SIRT1 overexpression with regard to the
inhibition of NF-B in both RIN cells and pancreatic islets,
SIRT1 activation could be a potential target for the devel-
opment of a type 1 diabetes drug.
Until now, the only known function of SIRT1 in pan-
creas was the regulation of insulin secretion through
suppression of uncoupling protein 2. Pancreatic -cell–
speciﬁc SIRT1-transgenic mice showed enhanced glucose-
stimulated insulin secretion (21,22). Here, we showed an
additional effect of SIRT1: Through inhibition of NF-Bb y
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350 DIABETES, VOL. 58, FEBRUARY 2009deacetylating p65, it could protect -cells from cytokine.
The precise mechanism by which SIRT1 inhibits cytokine-
mediated -cell death needs to be further elucidated;
however, our results suggest that SIRT1 may have diverse
roles in addition to regulating insulin secretion in pancre-
atic -cells and that it constitutes a novel mechanism for
treating type 1 diabetes.
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